Johnson & Johnson's coronavirus vaccine was 72 percent effective in the first data from a late-stage U.S. trial, the company said Friday. But the vaccine's efficacy fell to 52 percent against a virus variant first identified in South Africa.
The highly anticipated vaccine has several logistical advantages over authorized shots from Moderna and Pfizer: It is given as one dose and can be stored in refrigerators, rather than freezers.
The United States has purchased 100 million doses of the Johnson & Johnson vaccine with an option to buy an additional 200 million doses.
Read more: https://www.politico.com/news/2021/01/29/johnson-and-johnson-vaccine-efficacy-coronavirus-463732
To change your alert settings, please go to https://www.politico.com/_login?base=https%3A%2F%2Fwww.politico.com/settings.
This email was sent to edwardlorilla1986.paxforex@blogger.com by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA
Please click here and follow the steps to unsubscribe.
No comments:
Post a Comment